Hubalewska Alicja, Sowa-Staszczak Anna, Huszno Bohdan, Markocka Aneta, Pityński Kazimierz, Basta Antoni, Opławski Marcin, Basta Paweł
Department of Endocrinology, Nuclear Medicine Unit, Jagiellonian University, Kraków, Poland.
Nucl Med Rev Cent East Eur. 2003;6(2):127-30.
The initial draining lymph node for a primary tumor is referred to as the "sentinel" node. Firstly adopted in the management of patients with cutaneous melanoma and breast cancer, it is now widely tested in cervical cancer. In patients with cervical cancer, lymph node status is the most important prognostic factor for survival. In patients with cervical cancer FIGO stage I and II pelvic lymph node metastases are expected in 0-16 and 24.5-31% and para-aortic lymph node metastases are expected in 0-22 and 11-19% of patients. The removal of pelvic and para-aortic lymph nodes is essential for assessing the biology of the disease. Lymphoscintigraphy enables the visualisation of lymphatic drainage patterns from a great variety of tumour sites prior to surgery. Therefore, the current procedure is to perform the pre-operative mapping of sentinel nodes by static and/or dynamic lymphoscintigraphy, followed by in vivo identification using a gamma detection probe and selective surgical resection.
Between 2001-2003, 37 patients with cervical cancer FIGO stage I-IIa were seemed to be qualified to undergo lymphoscintigraphy. The day before surgery (99m)Tc-nanocolloid (100 MBq; 0.5-1.0 ml in volume) was applied in each quadrant of the cervix or around the tumor. The static scintigraphic scans were performed after 2 hours p.i. using a dual-head large-field-of-view Siemens gamma-camera equipped with high resolution collimators. SNs were identified intra-operatively using a handheld gamma detection probe (Navigator GPS-Tyco) and intra-operative lymphatic mapping with blue dye. After a resection of the SNs, a standard radical hysterectomy with pelvic and low para-aortic lymph node dissection was performed. Tumor characteristics were compared with sentinel node detection and with the histopathological and immunohistochemical results.
The scintigraphy showed a focal uptake in 35 of the 37 patients. In all women one or more sentinel lymph nodes were identified intra-operatively. Of them, 24 patients had those located bilaterally. Histologically positive SNs were found in 5 women (13.5%).
A combination pre-operatively administered radioactively labelled albumin with blue dye allows the successful detection of SN in patient with cervical cancer. This technique will result in a real advance in the less aggressive management of patients with early stage cervical cancer. Sentinel lymph node status may be representative of the pelvic lymph nodes status in cervical cancer and thus could provide important information for further treatment.
原发肿瘤的首个引流淋巴结被称为“前哨”淋巴结。该概念最初应用于皮肤黑色素瘤和乳腺癌患者的治疗,目前已在宫颈癌中广泛应用。在宫颈癌患者中,淋巴结状态是生存的最重要预后因素。在国际妇产科联盟(FIGO)分期为I期和II期的宫颈癌患者中,盆腔淋巴结转移率分别为0 - 16%和24.5 - 31%,腹主动脉旁淋巴结转移率分别为0 - 22%和11 - 19%。切除盆腔和腹主动脉旁淋巴结对于评估疾病生物学特性至关重要。淋巴闪烁造影能够在手术前显示来自各种肿瘤部位的淋巴引流模式。因此,目前的做法是通过静态和/或动态淋巴闪烁造影进行前哨淋巴结的术前定位,随后使用γ探测仪进行术中识别并进行选择性手术切除。
在2001 - 2003年间,37例FIGO分期为I - IIa期的宫颈癌患者似乎符合接受淋巴闪烁造影的条件。手术前一天,将(99m)锝纳米胶体(100 MBq;体积0.5 - 1.0 ml)注入宫颈的每个象限或肿瘤周围。注射后2小时,使用配备高分辨率准直器的双头大视野西门子γ相机进行静态闪烁扫描。术中使用手持式γ探测仪(Navigator GPS - Tyco)和蓝色染料进行术中淋巴管造影来识别前哨淋巴结。切除前哨淋巴结后,进行标准的根治性子宫切除术及盆腔和低位腹主动脉旁淋巴结清扫术。将肿瘤特征与前哨淋巴结检测结果以及组织病理学和免疫组织化学结果进行比较。
闪烁扫描显示37例患者中有35例出现局部摄取。所有女性患者术中均识别出一个或多个前哨淋巴结。其中,24例患者的前哨淋巴结位于双侧。5名女性(13.5%)的前哨淋巴结组织学检查呈阳性。
术前联合应用放射性标记白蛋白和蓝色染料能够成功检测宫颈癌患者的前哨淋巴结。该技术将在早期宫颈癌患者的微创治疗方面取得实质性进展。前哨淋巴结状态可能代表宫颈癌盆腔淋巴结状态,从而可为进一步治疗提供重要信息。